^
Association details:
| Biomarker: | FGFR3 K650E |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Published date:
11/01/2020
Excerpt:
Across all tumor types studied, futibatinib inhibited the growth of cell lines with various FGFR genomic aberrations, but not of cell lines that did not harbor such aberrations....These FGFR aberrations included FGFR1/2 amplifications (breast cancer), FGFR1 amplifications (lung cancer), FGFR2 amplifications (gastric cancer), FGFR2 point mutations (endometrial cancer), FGFR3 fusions (bladder cancer), and FGFR3 translocations (multiple myeloma; Table 1...).
DOI:
10.1158/0008-5472.CAN-19-2568
